Genome-wide association study of prostate cancer-specific survival

Robert Szulkin, Robert Karlsson, Thomas Whitington, Markus Aly, Henrik Gronberg, Rosalind A. Eeles, Douglas F. Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G. Giles, Melissa C. Southey, Liesel M. Fitzgerald, Brian E. Henderson, Fredrick R. Schumacher, Christopher A. Haiman, Csilla Sipeky, Teuvol J. Tammela, Børge G. NordestgaardTimothy J. Key, Ruth C. Travis, David E. Neal, Jenny L. Donovan, Freddie C. Hamdy, Paul D.P. Pharoah, Nora Pashayan, Kay Tee Khaw, Janet L. Stanford, Stephen N. Thibodeau, Shannon K. McDonnell, Daniel J. Schaid, Christiane Maier, Walther Vogel, Manuel Luedeke, Kathleen Herkommer, Adam S. Kibel, Cezary Cybulski, Jan Lubinski, Wojciech Kluzniak, Lisa Cannon-Albright, Hermann Brenner, Volker Herrmann, Bernd Holleczek, Jong Y. Park, Thomas A. Sellers, Hui Yi Lim, Chavdar Slavov, Radka P. Kaneva, Vanio I. Mitev, Amanda Spurdle, Manuel R. Teixeira, Paula Paulo, Sofia Maia, Hardev Pandha, Agnieszka Michael, Andrzej Kierzek, Jyotsna Batra, Judith A. Clements, Demetrius Albanes, Gerald L. Andriole, Sonja I. Berndt, Stephen Chanock, Susan M. Gapstur, Edward L. Giovannucci, David J. Hunter, Peter Kraft, Loic Le Marchand, Jing Ma, Alison M. Mondul, Kathryn L. Penney, Meir J. Stampfer, Victoria L. Stevens, Stephanie J. Weinstein, Antonia Trichopoulou, Bas H. Bueno-De-mesquita, Anne Tjønneland, David G. Cox, Lovise Maehle, Johanna Schleutker, Sara Lindstrom, Fredrik Wiklund

Research output: Article

19 Citations (Scopus)

Abstract

Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

Original languageEnglish
Pages (from-to)1796-1800
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number11
DOIs
Publication statusPublished - nov. 2015

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of 'Genome-wide association study of prostate cancer-specific survival'. Together they form a unique fingerprint.

  • Cite this

    Szulkin, R., Karlsson, R., Whitington, T., Aly, M., Gronberg, H., Eeles, R. A., Easton, D. F., Kote-Jarai, Z., Al Olama, A. A., Benlloch, S., Muir, K., Giles, G. G., Southey, M. C., Fitzgerald, L. M., Henderson, B. E., Schumacher, F. R., Haiman, C. A., Sipeky, C., Tammela, T. J., ... Wiklund, F. (2015). Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiology Biomarkers and Prevention, 24(11), 1796-1800. https://doi.org/10.1158/1055-9965.EPI-15-0543